US Restricts Use of GSK/Vir’s Xevudy, Deemed ‘Unlikely’ To Help Against Rising Omicron Variant
Lilly And AstraZeneca Antibodies Retain Potency
The constantly mutating SARS-CoV-2 has evaded yet another antibody therapy, but Vir and GSK hope that a higher dose of Xevudy could retain some efficacy against BA.2.
You may also be interested in...
Coronavirus Update: Vir, WuXi Terminate COVID-19 Antibody Pact
Xevudy, which was part of the deal, has already seen restrictions on its use due to diminished efficacy against Omicron. Plus, Ocugen is back in the game as the FDA has released the clinical hold on its Phase II/III vaccine trial, while Pfizer/BioNTech release new booster shot data for Comirnaty in children aged 6 months-5 years.
Merck/Ridgeback’s Lagevrio Could Get Another Chance As Others Face Limitations
New data for molnupiravir could mean new commercial life for Merck and Ridgeback’s oral COVID-19 therapy, which had fallen behind due to the outstanding efficacy for Pfizer’s Paxlovid.
Can Adagio’s Adintrevimab Hold Up Against Omicron BA.2?
The company will seek an EUA for the COVID-19 antibody after trial data indicated efficacy against Omicron, but studies have called into question its potency against the rapidly expanding subvariant.